Cure51
Updates & Highlights
Servier · about 24 hours ago
Servier and Cure51 launch a research partnership
Manufacturing Chemist · 1 day ago
Servier and Cure51 partner to identify new glioblastoma drug targets
GenomeWeb · over 1 year ago
In Brief This Week: Biodesix, Radiopharm Theranostics, Cure51, Fight Colorectal Cancer
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Cure51?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
7 recentServier and Cure51 launch a research partnership
Servier and Cure51 launch a research partnership
Servier · about 24 hours ago
Servier and Cure51 partner to identify new glioblastoma drug targets
Servier and Cure51 partner to identify new glioblastoma drug targets
Manufacturing Chemist · 1 day ago
In Brief This Week: Biodesix, Radiopharm Theranostics, Cure51, Fight Colorectal Cancer
In Brief This Week: Biodesix, Radiopharm Theranostics, Cure51, Fight Colorectal Cancer
GenomeWeb · over 1 year ago
The NVIDIA-Cure51 deal that ignites questions about biotech’s infrastructure future
The NVIDIA-Cure51 deal that ignites questions about biotech’s infrastructure future
Labiotech.eu · over 1 year ago
Cure51 Launches Major Study of Cancer “Super-Responders”
Cure51 Launches Major Study of Cancer “Super-Responders”
Inside Precision Medicine · almost 2 years ago
AbbVie inks deal with Parvus; Sofinnova invests in Cure51
AbbVie inks deal with Parvus; Sofinnova invests in Cure51
endpoints.news · over 2 years ago
Paris-based Cure51 raises €15 million to develop first-in-class treatments from exceptional cancer survivors
Paris-based Cure51 raises €15 million to develop first-in-class treatments from exceptional cancer survivors
EU-Startups · over 2 years ago